Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Cleasby, Anne ^a   Yon, Jeff ^a   Day, Philip J ^a   Richardson, Caroline ^a   Tickle, Ian J ^a   Williams, Pamela A ^a   Callahan, James F ^b   Carr, Robin ^c   Concha, Nestor ^b   Kerns, Jeffrey K ^b   Qi, Hongwei ^b   Sweitzer, Thomas ^b   Ward, Paris ^b   Davies, Thomas G ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE; CYSTEINE; ELECTROPHILE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN CUL3; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; 1-(2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OYL) IMIDAZOLE; IMIDAZOLE DERIVATIVE; KEAP1 PROTEIN, HUMAN; OLEANOLIC ACID; PROTEIN BINDING; SIGNAL PEPTIDE;

ARTICLE; BTB DOMAIN; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTALLIZATION; HUMAN; MUTANT; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; SYNTHESIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; GENETICS; MUTATION; STRUCTURE ACTIVITY RELATION;

BINDING SITES; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; OLEANOLIC ACID; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84902491159     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098896     Document Type: Article

References (71)

1. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24: 10941-10953. (Pubitemid 39603148)
2. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313-322. (Pubitemid 27373291)
3. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, et al. (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci U S A 101: 2040-2045. (Pubitemid 38229011)
4. Zhang M, An C, Gao Y, Leak RK, Chen J, et al. (2013) Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol 100: 30-47.
5. Stogios PJ, Downs GS, Jauhal JJ, Nandra SK, Prive GG (2005) Sequence and structural analysis of BTB domain proteins. Genome Biol 6: R82.
6. Magesh S, Chen Y, Hu L (2012) Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev 32: 687-726.
7. Ji AX, Prive GG (2013) Crystal structure of KLHL3 in complex with Cullin3. PLoS One 8: e60445.
8. Canning P, Cooper CD, Krojer T, Murray JW, Pike AC, et al. (2013) Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. J Biol Chem 288: 7803-7814.
9. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA (2004) The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24: 8477-8486. (Pubitemid 39245070)
10. Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, et al. (2007) Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 27: 7511-7521. (Pubitemid 350033657)
11. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, et al. (2006) Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol 26: 2887-2900.
12. Zipper LM, Mulcahy RT (2002) The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 277: 36544-36552.
13. Tong KI, Kobayashi A, Katsuoka F, Yamamoto M (2006) Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol Chem 387: 1311-1320. (Pubitemid 44691409)
14. Stogios PJ, Cuesta-Seijo JA, Chen L, Pomroy NC, Prive GG (2010) Insights into strand exchange in BTB domain dimers from the crystal structures of FAZF and Miz1. J Mol Biol 400: 983-997.
15. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, et al. (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 99: 11908-11913. (Pubitemid 34994497)
16. Eggler AL, Liu G, Pezzuto JM, van Breemen RB, Mesecar AD (2005) Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad Sci U S A 102: 10070-10075. (Pubitemid 41023327)
17. Hong F, Sekhar KR, Freeman ML, Liebler DC (2005) Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J Biol Chem 280: 31768-31775. (Pubitemid 41291926)
18. Hong F, Freeman ML, Liebler DC (2005) Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol 18: 1917-1926. (Pubitemid 43023050)
19. Zhang DD, Hannink M (2003) Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23: 8137-8151. (Pubitemid 37377505)
20. Levonen AL, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, et al. (2004) Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 378: 373-382. (Pubitemid 38367228)
21. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, et al. (2008) Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 28: 2758-2770. (Pubitemid 351542373)
22. Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC, et al. (2008) Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem Res Toxicol 21: 705-710. (Pubitemid 351498046)
23. Eggler AL, Small E, Hannink M, Mesecar AD (2009) Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1. Biochem J 422: 171-180.
24. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116.
25. Wasserman WW, Fahl WE (1997) Functional antioxidant responsive elements. Proc Natl Acad Sci U S A 94: 5361-5366. (Pubitemid 27214788)
26. Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, et al. (2009) Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci U S A 106: 250-255.
27. Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, et al. (2005) Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 202: 47-59. (Pubitemid 41002909)
28. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, et al. (2004) Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 114: 1248-1259. (Pubitemid 40385296)
29. Iizuka T, Ishii Y, Itoh K, Kiwamoto T, Kimura T, et al. (2005) Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 10: 1113-1125. (Pubitemid 41830071)
30. Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA, et al. (2009) The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal 11: 497-508.
31. Giudice A, Montella M (2006) Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention. Bioessays 28: 169-181.
32. Yates MS, Kensler TW (2007) Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect 20: 109-117. (Pubitemid 46917234)
33. Li J, Ichikawa T, Janicki JS, Cui T (2009) Targeting the Nrf2 pathway against cardiovascular disease. Expert Opin Ther Targets 13: 785-794.
34. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336.
35. Wilson AJ, Kerns JK, Callahan JF, Moody CJ (2013) Keap calm - and carry on covalently. J Med Chem 56: 7463-7476.
36. Luo Y, Eggler AL, Liu D, Liu G, Mesecar AD, et al. (2007) Sites of alkylation of human Keap1 by natural chemoprevention agents. J Am Soc Mass Spectrom 18: 2226-2232. (Pubitemid 350161332)
37. Holland R, Hawkins AE, Eggler AL, Mesecar AD, Fabris D, et al. (2008) Prospective type 1 and type 2 disulfides of Keap1 protein. Chem Res Toxicol 21: 2051-2060.
38. Kobayashi M, Li L, Iwamoto N, Nakajima-Takagi Y, Kaneko H, et al. (2009) The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 29: 493-502.
39. Hu C, Eggler AL, Mesecar AD, van Breemen RB (2011) Modification of keap1 cysteine residues by sulforaphane. Chem Res Toxicol 24: 515-521.
40. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, et al. (2005) Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 102: 4584-4589. (Pubitemid 40397155)
41. Hayes JD, Kelleher MO, Eggleston IM (2008) The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Nutr 47 Suppl 2: 73-88. (Pubitemid 351644183)
42. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, et al. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134: 678-692.
43. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, et al. (2006) Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 26: 221-229.
44. Eggler AL, Luo Y, van Breemen RB, Mesecar AD (2007) Identification of the highly reactive cysteine 151 in the chemopreventive agent-sensor Keap1 protein is method-dependent. Chem Res Toxicol 20: 1878-1884.
45. Baird L, Dinkova-Kostova AT (2013) Diffusion dynamics of the Keap1-Cullin3 interaction in single live cells. Biochem Biophys Res Commun 433: 58-65.
46. Takaya K, Suzuki T, Motohashi H, Onodera K, Satomi S, et al. (2012) Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med 53: 817-827.
47. Ichikawa T, Li J, Meyer CJ, Janicki JS, Hannink M, et al. (2009) Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes. PLoS One 4: e8391.
48. Ogura T, Tong KI, Mio K, Maruyama Y, Kurokawa H, et al. (2010) Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains. Proc Natl Acad Sci U S A 107:2842-2847.
49. McMahon M, Lamont DJ, Beattie KA, Hayes JD (2010) Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U S A 107: 18838-18843.
50. Errington WJ, Khan MQ, Bueler SA, Rubinstein JL, Chakrabartty A, et al. (2012) Adaptor protein self-assembly drives the control of a cullin-RING ubiquitin ligase. Structure 20: 1141-1153.
51. Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, et al. (2009) Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell 36: 39-50.
52. Gao L, Wang J, Sekhar KR, Yin H, Yared NF, et al. (2007) Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem 282: 2529-2537. (Pubitemid 47076775)
53. Niture SK, Jain AK, Jaiswal AK (2009) Antioxidant-induced modification of INrf2 cysteine 151 and PKC-delta-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. J Cell Sci 122: 4452-4464.
54. Davies TG, Tickle IJ (2012) Fragment screening using X-ray crystallography. Top Curr Chem 317: 33-59.
55. Saalau-Bethell SM, Woodhead AJ, Chessari G, Carr MG, Coyle J, et al. (2012) Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 8: 920-925.
56. Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, et al. (2012) Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491: 458-462.
57. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, et al. (1998) Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 8: 2711-2714. (Pubitemid 28496657)
58. Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro FG Jr, et al. (2000) Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem 43: 4233-4246.
59. Honda T, Janosik T, Honda Y, Han J, Liby KT, et al. (2004) Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. J Med Chem 47: 4923-4932. (Pubitemid 39238267)
60. Yang HJ, Li BG, Cai XH, Qi HY, Luo YG, et al. (2006) Chiral decalins: preparation from oleanolic acid and application in the synthesis of (-)-9-epiambrox. J Nat Prod 69: 1531-1538.
61. Kabsch W (2010) XDS. Acta Crystallogr D Biol Crystallogr 66: 125-132.
62. Evans P (2006) Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62: 72-82.
63. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67: 235-242.
64. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674. (Pubitemid 47080256)
65. Murshudov GN, Vagin AA, Dodson EJ (2004) Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallogr D D53: 240-255.
66. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132. (Pubitemid 41742764)
67. Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P, et al. (2011) BUSTER, Cambridge, United Kingdom: Global Phasing Ltd., version.
68. Mooij WT, Hartshorn MJ, Tickle IJ, Sharff AJ, Verdonk ML, et al. (2006) Automated Protein-Ligand Crystallography for Structure-Based Drug Design. ChemMedChem 1: 827-838. (Pubitemid 44384544)
69. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Research 28: 235-242. (Pubitemid 30047768)
70. Hartshorn MJ (2002) AstexViewer: a visualisation aid for structure-based drug design. J Comput Aided Mol Des 16: 871-881.
71. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947-2948. (Pubitemid 350162903)